NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $47.29 +1.19 (+2.58%) (As of 08/30/2024 08:55 PM ET) Add Compare Share Share Today's Range$45.64▼$47.4050-Day Range$39.87▼$53.8952-Week Range$20.97▼$53.92Volume249,000 shsAverage Volume561,558 shsMarket Capitalization$2.89 billionP/E RatioN/ADividend YieldN/APrice Target$55.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Rhythm Pharmaceuticals alerts: Email Address Rhythm Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside18.1% Upside$55.83 Price TargetShort InterestBearish16.16% of Shares Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.46Based on 13 Articles This WeekInsider TradingSelling Shares$3.48 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.44) to ($2.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector463rd out of 928 stocksPharmaceutical Preparations Industry212th out of 437 stocks 2.4 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.16% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 2.95%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 1.9 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,476,642.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Rhythm Pharmaceuticals is held by insiders.Read more about Rhythm Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.44) to ($2.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -10.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -10.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 73.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now. About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesAugust 29, 2024 | insidertrades.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 3,200 Shares of StockAugust 29, 2024 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Director Lynn A. Tetrault Sells 4,300 SharesSeptember 2, 2024 | The Oxford Club (Ad)Alex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.August 14, 2024 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $2,212,620.90 in StockAugust 31 at 8:11 AM | americanbankingnews.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $160,032.00 in StockAugust 30 at 8:49 AM | yahoo.comLow Flying Hawks Announce New Album Featuring Rhythm Section of Melvins’ Dale Crover and Mr. Bungle’s Trevor DunnAugust 30 at 8:49 AM | seekingalpha.comRhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)August 30 at 6:27 AM | americanbankingnews.comLynn A. Tetrault Sells 4,300 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockSeptember 2, 2024 | The Oxford Club (Ad)Alex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.August 28, 2024 | markets.businessinsider.comRhythm Pharma: FDA To Review Supplemental New Drug Application For IMCIVREE - Quick FactsAugust 26, 2024 | marketwatch.comRhythm Pharma Gets FDA Priority Review of Obesity Drug for ChildrenAugust 26, 2024 | markets.businessinsider.comRhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in SeptemberAugust 26, 2024 | globenewswire.comRhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years oldAugust 22, 2024 | msn.comSamsung Galaxy watches in India get ‘Irregular Heart Rhythm Notification’ featureAugust 21, 2024 | msn.comTickets on sale for Reno Rodeo Foundation’s annual Rhythm and Rawhide fundrasierAugust 21, 2024 | msn.comRhythm and Alps 2024: First line-up includes Becky Hill, Shapeshifter, Sir Dave Dobbyn and moreAugust 17, 2024 | yahoo.comGRAAHI Rhythm Run 5K and Health Fair returns to MLK Park on August 17August 14, 2024 | msn.comRhythm and blues festival announces additional programme featuresSee More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/02/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$55.83 High Stock Price Target$79.00 Low Stock Price Target$42.00 Potential Upside/Downside+18.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-254.88% Pretax Margin-253.57% Return on Equity-221.65% Return on Assets-78.17% Debt Debt-to-Equity RatioN/A Current Ratio6.53 Quick Ratio6.31 Sales & Book Value Annual Sales$77.43 million Price / Sales37.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book73.89Miscellaneous Outstanding Shares61,130,000Free Float57,559,000Market Cap$2.89 billion OptionableOptionable Beta2.04 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 70)Chairman, President & CEO Comp: $1.35MMr. Hunter C. Smith M.B.A. (Age 55)CFO & Treasurer Comp: $757.32kMr. Joseph Shulman (Age 48)Chief Technical Officer Comp: $677.27kMr. Yann Mazabraud (Age 51)Executive VP & Head of International Comp: $936.91kMs. Jennifer Lee (Age 48)Executive VP & Head of North America Comp: $727.14kMr. Christopher German (Age 53)Corporate Controller, Principal Accounting Officer & Executive Director Mr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 49)Chief Human Resources Officer More ExecutivesKey CompetitorsArvinasNASDAQ:ARVNPliant TherapeuticsNASDAQ:PLRXAnnexonNASDAQ:ANNXTheravance BiopharmaNASDAQ:TBPHCatalentNYSE:CTLTView All CompetitorsInsiders & InstitutionsClearbridge Investments LLCSold 1,896 shares on 8/27/2024Ownership: 0.145%Pamela J CramerSold 3,200 sharesTotal: $160,032.00 ($50.01/share)Lynn A TetraultSold 4,300 sharesTotal: $215,043.00 ($50.01/share)Perceptive Advisors LLCBought 178,000 shares on 8/16/2024Ownership: 5.638%Frazier Life Sciences Management L.P.Bought 181,125 shares on 8/16/2024Ownership: 3.879%View All Insider TransactionsView All Institutional Transactions RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $45.97 on January 1st, 2024. Since then, RYTM stock has increased by 2.9% and is now trading at $47.29. View the best growth stocks for 2024 here. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.16. Rhythm Pharmaceuticals's revenue was up 51.3% on a year-over-year basis. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Top institutional investors of Rhythm Pharmaceuticals include Primecap Management Co. CA (11.99%), Perceptive Advisors LLC (5.64%), Frazier Life Sciences Management L.P. (3.88%) and Federated Hermes Inc. (2.72%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, William T Roberts, Jennifer Chien, Lynn A Tetrault, Jennifer Kayden Lee, Christopher Paul German and Joseph Shulman. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN) and Kadmon (KDMN). This page (NASDAQ:RYTM) was last updated on 9/2/2024 by MarketBeat.com Staff From Our PartnersFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredFREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportun...Monument Traders Alliance | SponsoredBiden’s Big Fix America's Next Nightmare (has nothing to do with November) Roosevelt failed to make it work during World W...Stansberry Research | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts